<LCTL_TEXT lang="spa">
<DOC grammar="none" id="L0C04CVNC" lang="spa" raw_text_char_length="3929" raw_text_md5="e2c2867cab6f73bcd60f41af7236aa97" tokenization="tokenization_parameters.v5.0">
<TEXT>
<SEG end_char="67" id="segment-0" start_char="1">
<ORIGINAL_TEXT>Sofosbuvir/daclatasvir drugs may be effective coronavirus treatment</ORIGINAL_TEXT>
<TOKEN end_char="22" id="token-0-0" morph="none" pos="unknown" start_char="1">Sofosbuvir/daclatasvir</TOKEN>
<TOKEN end_char="28" id="token-0-1" morph="none" pos="word" start_char="24">drugs</TOKEN>
<TOKEN end_char="32" id="token-0-2" morph="none" pos="word" start_char="30">may</TOKEN>
<TOKEN end_char="35" id="token-0-3" morph="none" pos="word" start_char="34">be</TOKEN>
<TOKEN end_char="45" id="token-0-4" morph="none" pos="word" start_char="37">effective</TOKEN>
<TOKEN end_char="57" id="token-0-5" morph="none" pos="word" start_char="47">coronavirus</TOKEN>
<TOKEN end_char="67" id="token-0-6" morph="none" pos="word" start_char="59">treatment</TOKEN>
</SEG>
<SEG end_char="91" id="segment-1" start_char="71">
<ORIGINAL_TEXT>Several new papers in</ORIGINAL_TEXT>
<TOKEN end_char="77" id="token-1-0" morph="none" pos="word" start_char="71">Several</TOKEN>
<TOKEN end_char="81" id="token-1-1" morph="none" pos="word" start_char="79">new</TOKEN>
<TOKEN end_char="88" id="token-1-2" morph="none" pos="word" start_char="83">papers</TOKEN>
<TOKEN end_char="91" id="token-1-3" morph="none" pos="word" start_char="90">in</TOKEN>
</SEG>
<SEG end_char="130" id="segment-2" start_char="94">
<ORIGINAL_TEXT>Journal of Antimicrobial Chemotherapy</ORIGINAL_TEXT>
<TOKEN end_char="100" id="token-2-0" morph="none" pos="word" start_char="94">Journal</TOKEN>
<TOKEN end_char="103" id="token-2-1" morph="none" pos="word" start_char="102">of</TOKEN>
<TOKEN end_char="117" id="token-2-2" morph="none" pos="word" start_char="105">Antimicrobial</TOKEN>
<TOKEN end_char="130" id="token-2-3" morph="none" pos="word" start_char="119">Chemotherapy</TOKEN>
</SEG>
<SEG end_char="215" id="segment-3" start_char="133">
<ORIGINAL_TEXT>, published by Oxford University Press, suggest successful treatments for COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="133" id="token-3-0" morph="none" pos="punct" start_char="133">,</TOKEN>
<TOKEN end_char="143" id="token-3-1" morph="none" pos="word" start_char="135">published</TOKEN>
<TOKEN end_char="146" id="token-3-2" morph="none" pos="word" start_char="145">by</TOKEN>
<TOKEN end_char="153" id="token-3-3" morph="none" pos="word" start_char="148">Oxford</TOKEN>
<TOKEN end_char="164" id="token-3-4" morph="none" pos="word" start_char="155">University</TOKEN>
<TOKEN end_char="170" id="token-3-5" morph="none" pos="word" start_char="166">Press</TOKEN>
<TOKEN end_char="171" id="token-3-6" morph="none" pos="punct" start_char="171">,</TOKEN>
<TOKEN end_char="179" id="token-3-7" morph="none" pos="word" start_char="173">suggest</TOKEN>
<TOKEN end_char="190" id="token-3-8" morph="none" pos="word" start_char="181">successful</TOKEN>
<TOKEN end_char="201" id="token-3-9" morph="none" pos="word" start_char="192">treatments</TOKEN>
<TOKEN end_char="205" id="token-3-10" morph="none" pos="word" start_char="203">for</TOKEN>
<TOKEN end_char="214" id="token-3-11" morph="none" pos="unknown" start_char="207">COVID-19</TOKEN>
<TOKEN end_char="215" id="token-3-12" morph="none" pos="punct" start_char="215">.</TOKEN>
</SEG>
<SEG end_char="315" id="segment-4" start_char="218">
<ORIGINAL_TEXT>Three articles all researched the use of sofosbuvir and daclatasvir for the treatment of COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="222" id="token-4-0" morph="none" pos="word" start_char="218">Three</TOKEN>
<TOKEN end_char="231" id="token-4-1" morph="none" pos="word" start_char="224">articles</TOKEN>
<TOKEN end_char="235" id="token-4-2" morph="none" pos="word" start_char="233">all</TOKEN>
<TOKEN end_char="246" id="token-4-3" morph="none" pos="word" start_char="237">researched</TOKEN>
<TOKEN end_char="250" id="token-4-4" morph="none" pos="word" start_char="248">the</TOKEN>
<TOKEN end_char="254" id="token-4-5" morph="none" pos="word" start_char="252">use</TOKEN>
<TOKEN end_char="257" id="token-4-6" morph="none" pos="word" start_char="256">of</TOKEN>
<TOKEN end_char="268" id="token-4-7" morph="none" pos="word" start_char="259">sofosbuvir</TOKEN>
<TOKEN end_char="272" id="token-4-8" morph="none" pos="word" start_char="270">and</TOKEN>
<TOKEN end_char="284" id="token-4-9" morph="none" pos="word" start_char="274">daclatasvir</TOKEN>
<TOKEN end_char="288" id="token-4-10" morph="none" pos="word" start_char="286">for</TOKEN>
<TOKEN end_char="292" id="token-4-11" morph="none" pos="word" start_char="290">the</TOKEN>
<TOKEN end_char="302" id="token-4-12" morph="none" pos="word" start_char="294">treatment</TOKEN>
<TOKEN end_char="305" id="token-4-13" morph="none" pos="word" start_char="304">of</TOKEN>
<TOKEN end_char="314" id="token-4-14" morph="none" pos="unknown" start_char="307">COVID-19</TOKEN>
<TOKEN end_char="315" id="token-4-15" morph="none" pos="punct" start_char="315">.</TOKEN>
</SEG>
<SEG end_char="571" id="segment-5" start_char="317">
<ORIGINAL_TEXT>These three papers come from Iran, which has developed its own pill containing sofosbuvir and daclatasvir, and is in a position to test this in a large clinical trial as Iran is a massively impacted country, reporting some 2500 cases and 200 deaths a day.</ORIGINAL_TEXT>
<TOKEN end_char="321" id="token-5-0" morph="none" pos="word" start_char="317">These</TOKEN>
<TOKEN end_char="327" id="token-5-1" morph="none" pos="word" start_char="323">three</TOKEN>
<TOKEN end_char="334" id="token-5-2" morph="none" pos="word" start_char="329">papers</TOKEN>
<TOKEN end_char="339" id="token-5-3" morph="none" pos="word" start_char="336">come</TOKEN>
<TOKEN end_char="344" id="token-5-4" morph="none" pos="word" start_char="341">from</TOKEN>
<TOKEN end_char="349" id="token-5-5" morph="none" pos="word" start_char="346">Iran</TOKEN>
<TOKEN end_char="350" id="token-5-6" morph="none" pos="punct" start_char="350">,</TOKEN>
<TOKEN end_char="356" id="token-5-7" morph="none" pos="word" start_char="352">which</TOKEN>
<TOKEN end_char="360" id="token-5-8" morph="none" pos="word" start_char="358">has</TOKEN>
<TOKEN end_char="370" id="token-5-9" morph="none" pos="word" start_char="362">developed</TOKEN>
<TOKEN end_char="374" id="token-5-10" morph="none" pos="word" start_char="372">its</TOKEN>
<TOKEN end_char="378" id="token-5-11" morph="none" pos="word" start_char="376">own</TOKEN>
<TOKEN end_char="383" id="token-5-12" morph="none" pos="word" start_char="380">pill</TOKEN>
<TOKEN end_char="394" id="token-5-13" morph="none" pos="word" start_char="385">containing</TOKEN>
<TOKEN end_char="405" id="token-5-14" morph="none" pos="word" start_char="396">sofosbuvir</TOKEN>
<TOKEN end_char="409" id="token-5-15" morph="none" pos="word" start_char="407">and</TOKEN>
<TOKEN end_char="421" id="token-5-16" morph="none" pos="word" start_char="411">daclatasvir</TOKEN>
<TOKEN end_char="422" id="token-5-17" morph="none" pos="punct" start_char="422">,</TOKEN>
<TOKEN end_char="426" id="token-5-18" morph="none" pos="word" start_char="424">and</TOKEN>
<TOKEN end_char="429" id="token-5-19" morph="none" pos="word" start_char="428">is</TOKEN>
<TOKEN end_char="432" id="token-5-20" morph="none" pos="word" start_char="431">in</TOKEN>
<TOKEN end_char="434" id="token-5-21" morph="none" pos="word" start_char="434">a</TOKEN>
<TOKEN end_char="443" id="token-5-22" morph="none" pos="word" start_char="436">position</TOKEN>
<TOKEN end_char="446" id="token-5-23" morph="none" pos="word" start_char="445">to</TOKEN>
<TOKEN end_char="451" id="token-5-24" morph="none" pos="word" start_char="448">test</TOKEN>
<TOKEN end_char="456" id="token-5-25" morph="none" pos="word" start_char="453">this</TOKEN>
<TOKEN end_char="459" id="token-5-26" morph="none" pos="word" start_char="458">in</TOKEN>
<TOKEN end_char="461" id="token-5-27" morph="none" pos="word" start_char="461">a</TOKEN>
<TOKEN end_char="467" id="token-5-28" morph="none" pos="word" start_char="463">large</TOKEN>
<TOKEN end_char="476" id="token-5-29" morph="none" pos="word" start_char="469">clinical</TOKEN>
<TOKEN end_char="482" id="token-5-30" morph="none" pos="word" start_char="478">trial</TOKEN>
<TOKEN end_char="485" id="token-5-31" morph="none" pos="word" start_char="484">as</TOKEN>
<TOKEN end_char="490" id="token-5-32" morph="none" pos="word" start_char="487">Iran</TOKEN>
<TOKEN end_char="493" id="token-5-33" morph="none" pos="word" start_char="492">is</TOKEN>
<TOKEN end_char="495" id="token-5-34" morph="none" pos="word" start_char="495">a</TOKEN>
<TOKEN end_char="505" id="token-5-35" morph="none" pos="word" start_char="497">massively</TOKEN>
<TOKEN end_char="514" id="token-5-36" morph="none" pos="word" start_char="507">impacted</TOKEN>
<TOKEN end_char="522" id="token-5-37" morph="none" pos="word" start_char="516">country</TOKEN>
<TOKEN end_char="523" id="token-5-38" morph="none" pos="punct" start_char="523">,</TOKEN>
<TOKEN end_char="533" id="token-5-39" morph="none" pos="word" start_char="525">reporting</TOKEN>
<TOKEN end_char="538" id="token-5-40" morph="none" pos="word" start_char="535">some</TOKEN>
<TOKEN end_char="543" id="token-5-41" morph="none" pos="word" start_char="540">2500</TOKEN>
<TOKEN end_char="549" id="token-5-42" morph="none" pos="word" start_char="545">cases</TOKEN>
<TOKEN end_char="553" id="token-5-43" morph="none" pos="word" start_char="551">and</TOKEN>
<TOKEN end_char="557" id="token-5-44" morph="none" pos="word" start_char="555">200</TOKEN>
<TOKEN end_char="564" id="token-5-45" morph="none" pos="word" start_char="559">deaths</TOKEN>
<TOKEN end_char="566" id="token-5-46" morph="none" pos="word" start_char="566">a</TOKEN>
<TOKEN end_char="570" id="token-5-47" morph="none" pos="word" start_char="568">day</TOKEN>
<TOKEN end_char="571" id="token-5-48" morph="none" pos="punct" start_char="571">.</TOKEN>
</SEG>
<SEG end_char="647" id="segment-6" start_char="574">
<ORIGINAL_TEXT>Currently no effective antiviral therapy has been found to treat COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="582" id="token-6-0" morph="none" pos="word" start_char="574">Currently</TOKEN>
<TOKEN end_char="585" id="token-6-1" morph="none" pos="word" start_char="584">no</TOKEN>
<TOKEN end_char="595" id="token-6-2" morph="none" pos="word" start_char="587">effective</TOKEN>
<TOKEN end_char="605" id="token-6-3" morph="none" pos="word" start_char="597">antiviral</TOKEN>
<TOKEN end_char="613" id="token-6-4" morph="none" pos="word" start_char="607">therapy</TOKEN>
<TOKEN end_char="617" id="token-6-5" morph="none" pos="word" start_char="615">has</TOKEN>
<TOKEN end_char="622" id="token-6-6" morph="none" pos="word" start_char="619">been</TOKEN>
<TOKEN end_char="628" id="token-6-7" morph="none" pos="word" start_char="624">found</TOKEN>
<TOKEN end_char="631" id="token-6-8" morph="none" pos="word" start_char="630">to</TOKEN>
<TOKEN end_char="637" id="token-6-9" morph="none" pos="word" start_char="633">treat</TOKEN>
<TOKEN end_char="646" id="token-6-10" morph="none" pos="unknown" start_char="639">COVID-19</TOKEN>
<TOKEN end_char="647" id="token-6-11" morph="none" pos="punct" start_char="647">.</TOKEN>
</SEG>
<SEG end_char="870" id="segment-7" start_char="649">
<ORIGINAL_TEXT>The aim of the trials was to assess if the addition of sofosbuvir and daclatasvir, a drug combination commonly used for the treatment of hepatitis C, improved clinical outcomes in patients with moderate or severe COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="651" id="token-7-0" morph="none" pos="word" start_char="649">The</TOKEN>
<TOKEN end_char="655" id="token-7-1" morph="none" pos="word" start_char="653">aim</TOKEN>
<TOKEN end_char="658" id="token-7-2" morph="none" pos="word" start_char="657">of</TOKEN>
<TOKEN end_char="662" id="token-7-3" morph="none" pos="word" start_char="660">the</TOKEN>
<TOKEN end_char="669" id="token-7-4" morph="none" pos="word" start_char="664">trials</TOKEN>
<TOKEN end_char="673" id="token-7-5" morph="none" pos="word" start_char="671">was</TOKEN>
<TOKEN end_char="676" id="token-7-6" morph="none" pos="word" start_char="675">to</TOKEN>
<TOKEN end_char="683" id="token-7-7" morph="none" pos="word" start_char="678">assess</TOKEN>
<TOKEN end_char="686" id="token-7-8" morph="none" pos="word" start_char="685">if</TOKEN>
<TOKEN end_char="690" id="token-7-9" morph="none" pos="word" start_char="688">the</TOKEN>
<TOKEN end_char="699" id="token-7-10" morph="none" pos="word" start_char="692">addition</TOKEN>
<TOKEN end_char="702" id="token-7-11" morph="none" pos="word" start_char="701">of</TOKEN>
<TOKEN end_char="713" id="token-7-12" morph="none" pos="word" start_char="704">sofosbuvir</TOKEN>
<TOKEN end_char="717" id="token-7-13" morph="none" pos="word" start_char="715">and</TOKEN>
<TOKEN end_char="729" id="token-7-14" morph="none" pos="word" start_char="719">daclatasvir</TOKEN>
<TOKEN end_char="730" id="token-7-15" morph="none" pos="punct" start_char="730">,</TOKEN>
<TOKEN end_char="732" id="token-7-16" morph="none" pos="word" start_char="732">a</TOKEN>
<TOKEN end_char="737" id="token-7-17" morph="none" pos="word" start_char="734">drug</TOKEN>
<TOKEN end_char="749" id="token-7-18" morph="none" pos="word" start_char="739">combination</TOKEN>
<TOKEN end_char="758" id="token-7-19" morph="none" pos="word" start_char="751">commonly</TOKEN>
<TOKEN end_char="763" id="token-7-20" morph="none" pos="word" start_char="760">used</TOKEN>
<TOKEN end_char="767" id="token-7-21" morph="none" pos="word" start_char="765">for</TOKEN>
<TOKEN end_char="771" id="token-7-22" morph="none" pos="word" start_char="769">the</TOKEN>
<TOKEN end_char="781" id="token-7-23" morph="none" pos="word" start_char="773">treatment</TOKEN>
<TOKEN end_char="784" id="token-7-24" morph="none" pos="word" start_char="783">of</TOKEN>
<TOKEN end_char="794" id="token-7-25" morph="none" pos="word" start_char="786">hepatitis</TOKEN>
<TOKEN end_char="796" id="token-7-26" morph="none" pos="word" start_char="796">C</TOKEN>
<TOKEN end_char="797" id="token-7-27" morph="none" pos="punct" start_char="797">,</TOKEN>
<TOKEN end_char="806" id="token-7-28" morph="none" pos="word" start_char="799">improved</TOKEN>
<TOKEN end_char="815" id="token-7-29" morph="none" pos="word" start_char="808">clinical</TOKEN>
<TOKEN end_char="824" id="token-7-30" morph="none" pos="word" start_char="817">outcomes</TOKEN>
<TOKEN end_char="827" id="token-7-31" morph="none" pos="word" start_char="826">in</TOKEN>
<TOKEN end_char="836" id="token-7-32" morph="none" pos="word" start_char="829">patients</TOKEN>
<TOKEN end_char="841" id="token-7-33" morph="none" pos="word" start_char="838">with</TOKEN>
<TOKEN end_char="850" id="token-7-34" morph="none" pos="word" start_char="843">moderate</TOKEN>
<TOKEN end_char="853" id="token-7-35" morph="none" pos="word" start_char="852">or</TOKEN>
<TOKEN end_char="860" id="token-7-36" morph="none" pos="word" start_char="855">severe</TOKEN>
<TOKEN end_char="869" id="token-7-37" morph="none" pos="unknown" start_char="862">COVID-19</TOKEN>
<TOKEN end_char="870" id="token-7-38" morph="none" pos="punct" start_char="870">.</TOKEN>
</SEG>
<SEG end_char="990" id="segment-8" start_char="873">
<ORIGINAL_TEXT>In one trial, researchers recruited 66 patients and allocated them to either the treatment group or the control group.</ORIGINAL_TEXT>
<TOKEN end_char="874" id="token-8-0" morph="none" pos="word" start_char="873">In</TOKEN>
<TOKEN end_char="878" id="token-8-1" morph="none" pos="word" start_char="876">one</TOKEN>
<TOKEN end_char="884" id="token-8-2" morph="none" pos="word" start_char="880">trial</TOKEN>
<TOKEN end_char="885" id="token-8-3" morph="none" pos="punct" start_char="885">,</TOKEN>
<TOKEN end_char="897" id="token-8-4" morph="none" pos="word" start_char="887">researchers</TOKEN>
<TOKEN end_char="907" id="token-8-5" morph="none" pos="word" start_char="899">recruited</TOKEN>
<TOKEN end_char="910" id="token-8-6" morph="none" pos="word" start_char="909">66</TOKEN>
<TOKEN end_char="919" id="token-8-7" morph="none" pos="word" start_char="912">patients</TOKEN>
<TOKEN end_char="923" id="token-8-8" morph="none" pos="word" start_char="921">and</TOKEN>
<TOKEN end_char="933" id="token-8-9" morph="none" pos="word" start_char="925">allocated</TOKEN>
<TOKEN end_char="938" id="token-8-10" morph="none" pos="word" start_char="935">them</TOKEN>
<TOKEN end_char="941" id="token-8-11" morph="none" pos="word" start_char="940">to</TOKEN>
<TOKEN end_char="948" id="token-8-12" morph="none" pos="word" start_char="943">either</TOKEN>
<TOKEN end_char="952" id="token-8-13" morph="none" pos="word" start_char="950">the</TOKEN>
<TOKEN end_char="962" id="token-8-14" morph="none" pos="word" start_char="954">treatment</TOKEN>
<TOKEN end_char="968" id="token-8-15" morph="none" pos="word" start_char="964">group</TOKEN>
<TOKEN end_char="971" id="token-8-16" morph="none" pos="word" start_char="970">or</TOKEN>
<TOKEN end_char="975" id="token-8-17" morph="none" pos="word" start_char="973">the</TOKEN>
<TOKEN end_char="983" id="token-8-18" morph="none" pos="word" start_char="977">control</TOKEN>
<TOKEN end_char="989" id="token-8-19" morph="none" pos="word" start_char="985">group</TOKEN>
<TOKEN end_char="990" id="token-8-20" morph="none" pos="punct" start_char="990">.</TOKEN>
</SEG>
<SEG end_char="1096" id="segment-9" start_char="992">
<ORIGINAL_TEXT>Clinical recovery within 14 days was achieved by 88% in the treatment group and 67% in the control group.</ORIGINAL_TEXT>
<TOKEN end_char="999" id="token-9-0" morph="none" pos="word" start_char="992">Clinical</TOKEN>
<TOKEN end_char="1008" id="token-9-1" morph="none" pos="word" start_char="1001">recovery</TOKEN>
<TOKEN end_char="1015" id="token-9-2" morph="none" pos="word" start_char="1010">within</TOKEN>
<TOKEN end_char="1018" id="token-9-3" morph="none" pos="word" start_char="1017">14</TOKEN>
<TOKEN end_char="1023" id="token-9-4" morph="none" pos="word" start_char="1020">days</TOKEN>
<TOKEN end_char="1027" id="token-9-5" morph="none" pos="word" start_char="1025">was</TOKEN>
<TOKEN end_char="1036" id="token-9-6" morph="none" pos="word" start_char="1029">achieved</TOKEN>
<TOKEN end_char="1039" id="token-9-7" morph="none" pos="word" start_char="1038">by</TOKEN>
<TOKEN end_char="1042" id="token-9-8" morph="none" pos="word" start_char="1041">88</TOKEN>
<TOKEN end_char="1043" id="token-9-9" morph="none" pos="punct" start_char="1043">%</TOKEN>
<TOKEN end_char="1046" id="token-9-10" morph="none" pos="word" start_char="1045">in</TOKEN>
<TOKEN end_char="1050" id="token-9-11" morph="none" pos="word" start_char="1048">the</TOKEN>
<TOKEN end_char="1060" id="token-9-12" morph="none" pos="word" start_char="1052">treatment</TOKEN>
<TOKEN end_char="1066" id="token-9-13" morph="none" pos="word" start_char="1062">group</TOKEN>
<TOKEN end_char="1070" id="token-9-14" morph="none" pos="word" start_char="1068">and</TOKEN>
<TOKEN end_char="1073" id="token-9-15" morph="none" pos="word" start_char="1072">67</TOKEN>
<TOKEN end_char="1074" id="token-9-16" morph="none" pos="punct" start_char="1074">%</TOKEN>
<TOKEN end_char="1077" id="token-9-17" morph="none" pos="word" start_char="1076">in</TOKEN>
<TOKEN end_char="1081" id="token-9-18" morph="none" pos="word" start_char="1079">the</TOKEN>
<TOKEN end_char="1089" id="token-9-19" morph="none" pos="word" start_char="1083">control</TOKEN>
<TOKEN end_char="1095" id="token-9-20" morph="none" pos="word" start_char="1091">group</TOKEN>
<TOKEN end_char="1096" id="token-9-21" morph="none" pos="punct" start_char="1096">.</TOKEN>
</SEG>
<SEG end_char="1221" id="segment-10" start_char="1098">
<ORIGINAL_TEXT>The treatment group had a significantly shorter median duration of hospitalization (6 days) than the control group (8 days).</ORIGINAL_TEXT>
<TOKEN end_char="1100" id="token-10-0" morph="none" pos="word" start_char="1098">The</TOKEN>
<TOKEN end_char="1110" id="token-10-1" morph="none" pos="word" start_char="1102">treatment</TOKEN>
<TOKEN end_char="1116" id="token-10-2" morph="none" pos="word" start_char="1112">group</TOKEN>
<TOKEN end_char="1120" id="token-10-3" morph="none" pos="word" start_char="1118">had</TOKEN>
<TOKEN end_char="1122" id="token-10-4" morph="none" pos="word" start_char="1122">a</TOKEN>
<TOKEN end_char="1136" id="token-10-5" morph="none" pos="word" start_char="1124">significantly</TOKEN>
<TOKEN end_char="1144" id="token-10-6" morph="none" pos="word" start_char="1138">shorter</TOKEN>
<TOKEN end_char="1151" id="token-10-7" morph="none" pos="word" start_char="1146">median</TOKEN>
<TOKEN end_char="1160" id="token-10-8" morph="none" pos="word" start_char="1153">duration</TOKEN>
<TOKEN end_char="1163" id="token-10-9" morph="none" pos="word" start_char="1162">of</TOKEN>
<TOKEN end_char="1179" id="token-10-10" morph="none" pos="word" start_char="1165">hospitalization</TOKEN>
<TOKEN end_char="1181" id="token-10-11" morph="none" pos="punct" start_char="1181">(</TOKEN>
<TOKEN end_char="1182" id="token-10-12" morph="none" pos="word" start_char="1182">6</TOKEN>
<TOKEN end_char="1187" id="token-10-13" morph="none" pos="word" start_char="1184">days</TOKEN>
<TOKEN end_char="1188" id="token-10-14" morph="none" pos="punct" start_char="1188">)</TOKEN>
<TOKEN end_char="1193" id="token-10-15" morph="none" pos="word" start_char="1190">than</TOKEN>
<TOKEN end_char="1197" id="token-10-16" morph="none" pos="word" start_char="1195">the</TOKEN>
<TOKEN end_char="1205" id="token-10-17" morph="none" pos="word" start_char="1199">control</TOKEN>
<TOKEN end_char="1211" id="token-10-18" morph="none" pos="word" start_char="1207">group</TOKEN>
<TOKEN end_char="1213" id="token-10-19" morph="none" pos="punct" start_char="1213">(</TOKEN>
<TOKEN end_char="1214" id="token-10-20" morph="none" pos="word" start_char="1214">8</TOKEN>
<TOKEN end_char="1219" id="token-10-21" morph="none" pos="word" start_char="1216">days</TOKEN>
<TOKEN end_char="1221" id="token-10-22" morph="none" pos="punct" start_char="1220">).</TOKEN>
</SEG>
<SEG end_char="1328" id="segment-11" start_char="1223">
<ORIGINAL_TEXT>Cumulative incidence of hospital discharge was significantly higher in the treatment group versus control.</ORIGINAL_TEXT>
<TOKEN end_char="1232" id="token-11-0" morph="none" pos="word" start_char="1223">Cumulative</TOKEN>
<TOKEN end_char="1242" id="token-11-1" morph="none" pos="word" start_char="1234">incidence</TOKEN>
<TOKEN end_char="1245" id="token-11-2" morph="none" pos="word" start_char="1244">of</TOKEN>
<TOKEN end_char="1254" id="token-11-3" morph="none" pos="word" start_char="1247">hospital</TOKEN>
<TOKEN end_char="1264" id="token-11-4" morph="none" pos="word" start_char="1256">discharge</TOKEN>
<TOKEN end_char="1268" id="token-11-5" morph="none" pos="word" start_char="1266">was</TOKEN>
<TOKEN end_char="1282" id="token-11-6" morph="none" pos="word" start_char="1270">significantly</TOKEN>
<TOKEN end_char="1289" id="token-11-7" morph="none" pos="word" start_char="1284">higher</TOKEN>
<TOKEN end_char="1292" id="token-11-8" morph="none" pos="word" start_char="1291">in</TOKEN>
<TOKEN end_char="1296" id="token-11-9" morph="none" pos="word" start_char="1294">the</TOKEN>
<TOKEN end_char="1306" id="token-11-10" morph="none" pos="word" start_char="1298">treatment</TOKEN>
<TOKEN end_char="1312" id="token-11-11" morph="none" pos="word" start_char="1308">group</TOKEN>
<TOKEN end_char="1319" id="token-11-12" morph="none" pos="word" start_char="1314">versus</TOKEN>
<TOKEN end_char="1327" id="token-11-13" morph="none" pos="word" start_char="1321">control</TOKEN>
<TOKEN end_char="1328" id="token-11-14" morph="none" pos="punct" start_char="1328">.</TOKEN>
</SEG>
<SEG end_char="1402" id="segment-12" start_char="1330">
<ORIGINAL_TEXT>Three patients died in the treatment group and five in the control group.</ORIGINAL_TEXT>
<TOKEN end_char="1334" id="token-12-0" morph="none" pos="word" start_char="1330">Three</TOKEN>
<TOKEN end_char="1343" id="token-12-1" morph="none" pos="word" start_char="1336">patients</TOKEN>
<TOKEN end_char="1348" id="token-12-2" morph="none" pos="word" start_char="1345">died</TOKEN>
<TOKEN end_char="1351" id="token-12-3" morph="none" pos="word" start_char="1350">in</TOKEN>
<TOKEN end_char="1355" id="token-12-4" morph="none" pos="word" start_char="1353">the</TOKEN>
<TOKEN end_char="1365" id="token-12-5" morph="none" pos="word" start_char="1357">treatment</TOKEN>
<TOKEN end_char="1371" id="token-12-6" morph="none" pos="word" start_char="1367">group</TOKEN>
<TOKEN end_char="1375" id="token-12-7" morph="none" pos="word" start_char="1373">and</TOKEN>
<TOKEN end_char="1380" id="token-12-8" morph="none" pos="word" start_char="1377">five</TOKEN>
<TOKEN end_char="1383" id="token-12-9" morph="none" pos="word" start_char="1382">in</TOKEN>
<TOKEN end_char="1387" id="token-12-10" morph="none" pos="word" start_char="1385">the</TOKEN>
<TOKEN end_char="1395" id="token-12-11" morph="none" pos="word" start_char="1389">control</TOKEN>
<TOKEN end_char="1401" id="token-12-12" morph="none" pos="word" start_char="1397">group</TOKEN>
<TOKEN end_char="1402" id="token-12-13" morph="none" pos="punct" start_char="1402">.</TOKEN>
</SEG>
<SEG end_char="1443" id="segment-13" start_char="1404">
<ORIGINAL_TEXT>No serious adverse events were reported.</ORIGINAL_TEXT>
<TOKEN end_char="1405" id="token-13-0" morph="none" pos="word" start_char="1404">No</TOKEN>
<TOKEN end_char="1413" id="token-13-1" morph="none" pos="word" start_char="1407">serious</TOKEN>
<TOKEN end_char="1421" id="token-13-2" morph="none" pos="word" start_char="1415">adverse</TOKEN>
<TOKEN end_char="1428" id="token-13-3" morph="none" pos="word" start_char="1423">events</TOKEN>
<TOKEN end_char="1433" id="token-13-4" morph="none" pos="word" start_char="1430">were</TOKEN>
<TOKEN end_char="1442" id="token-13-5" morph="none" pos="word" start_char="1435">reported</TOKEN>
<TOKEN end_char="1443" id="token-13-6" morph="none" pos="punct" start_char="1443">.</TOKEN>
</SEG>
<SEG end_char="1607" id="segment-14" start_char="1446">
<ORIGINAL_TEXT>In another study, subjects suffering from COVID-19 were divided into two groups with one group receiving ribavirin and the other receiving sofosbuvir/daclatasvir.</ORIGINAL_TEXT>
<TOKEN end_char="1447" id="token-14-0" morph="none" pos="word" start_char="1446">In</TOKEN>
<TOKEN end_char="1455" id="token-14-1" morph="none" pos="word" start_char="1449">another</TOKEN>
<TOKEN end_char="1461" id="token-14-2" morph="none" pos="word" start_char="1457">study</TOKEN>
<TOKEN end_char="1462" id="token-14-3" morph="none" pos="punct" start_char="1462">,</TOKEN>
<TOKEN end_char="1471" id="token-14-4" morph="none" pos="word" start_char="1464">subjects</TOKEN>
<TOKEN end_char="1481" id="token-14-5" morph="none" pos="word" start_char="1473">suffering</TOKEN>
<TOKEN end_char="1486" id="token-14-6" morph="none" pos="word" start_char="1483">from</TOKEN>
<TOKEN end_char="1495" id="token-14-7" morph="none" pos="unknown" start_char="1488">COVID-19</TOKEN>
<TOKEN end_char="1500" id="token-14-8" morph="none" pos="word" start_char="1497">were</TOKEN>
<TOKEN end_char="1508" id="token-14-9" morph="none" pos="word" start_char="1502">divided</TOKEN>
<TOKEN end_char="1513" id="token-14-10" morph="none" pos="word" start_char="1510">into</TOKEN>
<TOKEN end_char="1517" id="token-14-11" morph="none" pos="word" start_char="1515">two</TOKEN>
<TOKEN end_char="1524" id="token-14-12" morph="none" pos="word" start_char="1519">groups</TOKEN>
<TOKEN end_char="1529" id="token-14-13" morph="none" pos="word" start_char="1526">with</TOKEN>
<TOKEN end_char="1533" id="token-14-14" morph="none" pos="word" start_char="1531">one</TOKEN>
<TOKEN end_char="1539" id="token-14-15" morph="none" pos="word" start_char="1535">group</TOKEN>
<TOKEN end_char="1549" id="token-14-16" morph="none" pos="word" start_char="1541">receiving</TOKEN>
<TOKEN end_char="1559" id="token-14-17" morph="none" pos="word" start_char="1551">ribavirin</TOKEN>
<TOKEN end_char="1563" id="token-14-18" morph="none" pos="word" start_char="1561">and</TOKEN>
<TOKEN end_char="1567" id="token-14-19" morph="none" pos="word" start_char="1565">the</TOKEN>
<TOKEN end_char="1573" id="token-14-20" morph="none" pos="word" start_char="1569">other</TOKEN>
<TOKEN end_char="1583" id="token-14-21" morph="none" pos="word" start_char="1575">receiving</TOKEN>
<TOKEN end_char="1606" id="token-14-22" morph="none" pos="unknown" start_char="1585">sofosbuvir/daclatasvir</TOKEN>
<TOKEN end_char="1607" id="token-14-23" morph="none" pos="punct" start_char="1607">.</TOKEN>
</SEG>
<SEG end_char="1763" id="segment-15" start_char="1609">
<ORIGINAL_TEXT>All participants also received the recommended national standard treatment which, at that time, was lopinavir/ritonavir and single-dose hydroxychloroquine.</ORIGINAL_TEXT>
<TOKEN end_char="1611" id="token-15-0" morph="none" pos="word" start_char="1609">All</TOKEN>
<TOKEN end_char="1624" id="token-15-1" morph="none" pos="word" start_char="1613">participants</TOKEN>
<TOKEN end_char="1629" id="token-15-2" morph="none" pos="word" start_char="1626">also</TOKEN>
<TOKEN end_char="1638" id="token-15-3" morph="none" pos="word" start_char="1631">received</TOKEN>
<TOKEN end_char="1642" id="token-15-4" morph="none" pos="word" start_char="1640">the</TOKEN>
<TOKEN end_char="1654" id="token-15-5" morph="none" pos="word" start_char="1644">recommended</TOKEN>
<TOKEN end_char="1663" id="token-15-6" morph="none" pos="word" start_char="1656">national</TOKEN>
<TOKEN end_char="1672" id="token-15-7" morph="none" pos="word" start_char="1665">standard</TOKEN>
<TOKEN end_char="1682" id="token-15-8" morph="none" pos="word" start_char="1674">treatment</TOKEN>
<TOKEN end_char="1688" id="token-15-9" morph="none" pos="word" start_char="1684">which</TOKEN>
<TOKEN end_char="1689" id="token-15-10" morph="none" pos="punct" start_char="1689">,</TOKEN>
<TOKEN end_char="1692" id="token-15-11" morph="none" pos="word" start_char="1691">at</TOKEN>
<TOKEN end_char="1697" id="token-15-12" morph="none" pos="word" start_char="1694">that</TOKEN>
<TOKEN end_char="1702" id="token-15-13" morph="none" pos="word" start_char="1699">time</TOKEN>
<TOKEN end_char="1703" id="token-15-14" morph="none" pos="punct" start_char="1703">,</TOKEN>
<TOKEN end_char="1707" id="token-15-15" morph="none" pos="word" start_char="1705">was</TOKEN>
<TOKEN end_char="1727" id="token-15-16" morph="none" pos="unknown" start_char="1709">lopinavir/ritonavir</TOKEN>
<TOKEN end_char="1731" id="token-15-17" morph="none" pos="word" start_char="1729">and</TOKEN>
<TOKEN end_char="1743" id="token-15-18" morph="none" pos="unknown" start_char="1733">single-dose</TOKEN>
<TOKEN end_char="1762" id="token-15-19" morph="none" pos="word" start_char="1745">hydroxychloroquine</TOKEN>
<TOKEN end_char="1763" id="token-15-20" morph="none" pos="punct" start_char="1763">.</TOKEN>
</SEG>
<SEG end_char="1905" id="segment-16" start_char="1766">
<ORIGINAL_TEXT>The results indicated that median duration of stay was five days for the sofosbuvir/daclatasvir group and nine days for the ribavirin group.</ORIGINAL_TEXT>
<TOKEN end_char="1768" id="token-16-0" morph="none" pos="word" start_char="1766">The</TOKEN>
<TOKEN end_char="1776" id="token-16-1" morph="none" pos="word" start_char="1770">results</TOKEN>
<TOKEN end_char="1786" id="token-16-2" morph="none" pos="word" start_char="1778">indicated</TOKEN>
<TOKEN end_char="1791" id="token-16-3" morph="none" pos="word" start_char="1788">that</TOKEN>
<TOKEN end_char="1798" id="token-16-4" morph="none" pos="word" start_char="1793">median</TOKEN>
<TOKEN end_char="1807" id="token-16-5" morph="none" pos="word" start_char="1800">duration</TOKEN>
<TOKEN end_char="1810" id="token-16-6" morph="none" pos="word" start_char="1809">of</TOKEN>
<TOKEN end_char="1815" id="token-16-7" morph="none" pos="word" start_char="1812">stay</TOKEN>
<TOKEN end_char="1819" id="token-16-8" morph="none" pos="word" start_char="1817">was</TOKEN>
<TOKEN end_char="1824" id="token-16-9" morph="none" pos="word" start_char="1821">five</TOKEN>
<TOKEN end_char="1829" id="token-16-10" morph="none" pos="word" start_char="1826">days</TOKEN>
<TOKEN end_char="1833" id="token-16-11" morph="none" pos="word" start_char="1831">for</TOKEN>
<TOKEN end_char="1837" id="token-16-12" morph="none" pos="word" start_char="1835">the</TOKEN>
<TOKEN end_char="1860" id="token-16-13" morph="none" pos="unknown" start_char="1839">sofosbuvir/daclatasvir</TOKEN>
<TOKEN end_char="1866" id="token-16-14" morph="none" pos="word" start_char="1862">group</TOKEN>
<TOKEN end_char="1870" id="token-16-15" morph="none" pos="word" start_char="1868">and</TOKEN>
<TOKEN end_char="1875" id="token-16-16" morph="none" pos="word" start_char="1872">nine</TOKEN>
<TOKEN end_char="1880" id="token-16-17" morph="none" pos="word" start_char="1877">days</TOKEN>
<TOKEN end_char="1884" id="token-16-18" morph="none" pos="word" start_char="1882">for</TOKEN>
<TOKEN end_char="1888" id="token-16-19" morph="none" pos="word" start_char="1886">the</TOKEN>
<TOKEN end_char="1898" id="token-16-20" morph="none" pos="word" start_char="1890">ribavirin</TOKEN>
<TOKEN end_char="1904" id="token-16-21" morph="none" pos="word" start_char="1900">group</TOKEN>
<TOKEN end_char="1905" id="token-16-22" morph="none" pos="punct" start_char="1905">.</TOKEN>
</SEG>
<SEG end_char="1995" id="segment-17" start_char="1907">
<ORIGINAL_TEXT>The mortality in the sofosbuvir/daclatasvir group was 6% and 33% for the ribavirin group.</ORIGINAL_TEXT>
<TOKEN end_char="1909" id="token-17-0" morph="none" pos="word" start_char="1907">The</TOKEN>
<TOKEN end_char="1919" id="token-17-1" morph="none" pos="word" start_char="1911">mortality</TOKEN>
<TOKEN end_char="1922" id="token-17-2" morph="none" pos="word" start_char="1921">in</TOKEN>
<TOKEN end_char="1926" id="token-17-3" morph="none" pos="word" start_char="1924">the</TOKEN>
<TOKEN end_char="1949" id="token-17-4" morph="none" pos="unknown" start_char="1928">sofosbuvir/daclatasvir</TOKEN>
<TOKEN end_char="1955" id="token-17-5" morph="none" pos="word" start_char="1951">group</TOKEN>
<TOKEN end_char="1959" id="token-17-6" morph="none" pos="word" start_char="1957">was</TOKEN>
<TOKEN end_char="1961" id="token-17-7" morph="none" pos="word" start_char="1961">6</TOKEN>
<TOKEN end_char="1962" id="token-17-8" morph="none" pos="punct" start_char="1962">%</TOKEN>
<TOKEN end_char="1966" id="token-17-9" morph="none" pos="word" start_char="1964">and</TOKEN>
<TOKEN end_char="1969" id="token-17-10" morph="none" pos="word" start_char="1968">33</TOKEN>
<TOKEN end_char="1970" id="token-17-11" morph="none" pos="punct" start_char="1970">%</TOKEN>
<TOKEN end_char="1974" id="token-17-12" morph="none" pos="word" start_char="1972">for</TOKEN>
<TOKEN end_char="1978" id="token-17-13" morph="none" pos="word" start_char="1976">the</TOKEN>
<TOKEN end_char="1988" id="token-17-14" morph="none" pos="word" start_char="1980">ribavirin</TOKEN>
<TOKEN end_char="1994" id="token-17-15" morph="none" pos="word" start_char="1990">group</TOKEN>
<TOKEN end_char="1995" id="token-17-16" morph="none" pos="punct" start_char="1995">.</TOKEN>
</SEG>
<SEG end_char="2082" id="segment-18" start_char="1997">
<ORIGINAL_TEXT>The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17%.</ORIGINAL_TEXT>
<TOKEN end_char="1999" id="token-18-0" morph="none" pos="word" start_char="1997">The</TOKEN>
<TOKEN end_char="2008" id="token-18-1" morph="none" pos="word" start_char="2001">relative</TOKEN>
<TOKEN end_char="2013" id="token-18-2" morph="none" pos="word" start_char="2010">risk</TOKEN>
<TOKEN end_char="2016" id="token-18-3" morph="none" pos="word" start_char="2015">of</TOKEN>
<TOKEN end_char="2022" id="token-18-4" morph="none" pos="word" start_char="2018">death</TOKEN>
<TOKEN end_char="2026" id="token-18-5" morph="none" pos="word" start_char="2024">for</TOKEN>
<TOKEN end_char="2035" id="token-18-6" morph="none" pos="word" start_char="2028">patients</TOKEN>
<TOKEN end_char="2043" id="token-18-7" morph="none" pos="word" start_char="2037">treated</TOKEN>
<TOKEN end_char="2048" id="token-18-8" morph="none" pos="word" start_char="2045">with</TOKEN>
<TOKEN end_char="2071" id="token-18-9" morph="none" pos="unknown" start_char="2050">sofosbuvir/daclatasvir</TOKEN>
<TOKEN end_char="2075" id="token-18-10" morph="none" pos="word" start_char="2073">was</TOKEN>
<TOKEN end_char="2080" id="token-18-11" morph="none" pos="unknown" start_char="2077">0.17</TOKEN>
<TOKEN end_char="2082" id="token-18-12" morph="none" pos="punct" start_char="2081">%.</TOKEN>
</SEG>
<SEG end_char="2282" id="segment-19" start_char="2085">
<ORIGINAL_TEXT>The results of these studies suggest that the addition of sofosbuvir and daclatasvir to standard care may reduce the duration of hospital stays for COVID-19 patients compared to standard care alone.</ORIGINAL_TEXT>
<TOKEN end_char="2087" id="token-19-0" morph="none" pos="word" start_char="2085">The</TOKEN>
<TOKEN end_char="2095" id="token-19-1" morph="none" pos="word" start_char="2089">results</TOKEN>
<TOKEN end_char="2098" id="token-19-2" morph="none" pos="word" start_char="2097">of</TOKEN>
<TOKEN end_char="2104" id="token-19-3" morph="none" pos="word" start_char="2100">these</TOKEN>
<TOKEN end_char="2112" id="token-19-4" morph="none" pos="word" start_char="2106">studies</TOKEN>
<TOKEN end_char="2120" id="token-19-5" morph="none" pos="word" start_char="2114">suggest</TOKEN>
<TOKEN end_char="2125" id="token-19-6" morph="none" pos="word" start_char="2122">that</TOKEN>
<TOKEN end_char="2129" id="token-19-7" morph="none" pos="word" start_char="2127">the</TOKEN>
<TOKEN end_char="2138" id="token-19-8" morph="none" pos="word" start_char="2131">addition</TOKEN>
<TOKEN end_char="2141" id="token-19-9" morph="none" pos="word" start_char="2140">of</TOKEN>
<TOKEN end_char="2152" id="token-19-10" morph="none" pos="word" start_char="2143">sofosbuvir</TOKEN>
<TOKEN end_char="2156" id="token-19-11" morph="none" pos="word" start_char="2154">and</TOKEN>
<TOKEN end_char="2168" id="token-19-12" morph="none" pos="word" start_char="2158">daclatasvir</TOKEN>
<TOKEN end_char="2171" id="token-19-13" morph="none" pos="word" start_char="2170">to</TOKEN>
<TOKEN end_char="2180" id="token-19-14" morph="none" pos="word" start_char="2173">standard</TOKEN>
<TOKEN end_char="2185" id="token-19-15" morph="none" pos="word" start_char="2182">care</TOKEN>
<TOKEN end_char="2189" id="token-19-16" morph="none" pos="word" start_char="2187">may</TOKEN>
<TOKEN end_char="2196" id="token-19-17" morph="none" pos="word" start_char="2191">reduce</TOKEN>
<TOKEN end_char="2200" id="token-19-18" morph="none" pos="word" start_char="2198">the</TOKEN>
<TOKEN end_char="2209" id="token-19-19" morph="none" pos="word" start_char="2202">duration</TOKEN>
<TOKEN end_char="2212" id="token-19-20" morph="none" pos="word" start_char="2211">of</TOKEN>
<TOKEN end_char="2221" id="token-19-21" morph="none" pos="word" start_char="2214">hospital</TOKEN>
<TOKEN end_char="2227" id="token-19-22" morph="none" pos="word" start_char="2223">stays</TOKEN>
<TOKEN end_char="2231" id="token-19-23" morph="none" pos="word" start_char="2229">for</TOKEN>
<TOKEN end_char="2240" id="token-19-24" morph="none" pos="unknown" start_char="2233">COVID-19</TOKEN>
<TOKEN end_char="2249" id="token-19-25" morph="none" pos="word" start_char="2242">patients</TOKEN>
<TOKEN end_char="2258" id="token-19-26" morph="none" pos="word" start_char="2251">compared</TOKEN>
<TOKEN end_char="2261" id="token-19-27" morph="none" pos="word" start_char="2260">to</TOKEN>
<TOKEN end_char="2270" id="token-19-28" morph="none" pos="word" start_char="2263">standard</TOKEN>
<TOKEN end_char="2275" id="token-19-29" morph="none" pos="word" start_char="2272">care</TOKEN>
<TOKEN end_char="2281" id="token-19-30" morph="none" pos="word" start_char="2277">alone</TOKEN>
<TOKEN end_char="2282" id="token-19-31" morph="none" pos="punct" start_char="2282">.</TOKEN>
</SEG>
<SEG end_char="2361" id="segment-20" start_char="2285">
<ORIGINAL_TEXT>"Despite the encouraging initial results, it is too early to reach a verdict.</ORIGINAL_TEXT>
<TOKEN end_char="2285" id="token-20-0" morph="none" pos="punct" start_char="2285">"</TOKEN>
<TOKEN end_char="2292" id="token-20-1" morph="none" pos="word" start_char="2286">Despite</TOKEN>
<TOKEN end_char="2296" id="token-20-2" morph="none" pos="word" start_char="2294">the</TOKEN>
<TOKEN end_char="2308" id="token-20-3" morph="none" pos="word" start_char="2298">encouraging</TOKEN>
<TOKEN end_char="2316" id="token-20-4" morph="none" pos="word" start_char="2310">initial</TOKEN>
<TOKEN end_char="2324" id="token-20-5" morph="none" pos="word" start_char="2318">results</TOKEN>
<TOKEN end_char="2325" id="token-20-6" morph="none" pos="punct" start_char="2325">,</TOKEN>
<TOKEN end_char="2328" id="token-20-7" morph="none" pos="word" start_char="2327">it</TOKEN>
<TOKEN end_char="2331" id="token-20-8" morph="none" pos="word" start_char="2330">is</TOKEN>
<TOKEN end_char="2335" id="token-20-9" morph="none" pos="word" start_char="2333">too</TOKEN>
<TOKEN end_char="2341" id="token-20-10" morph="none" pos="word" start_char="2337">early</TOKEN>
<TOKEN end_char="2344" id="token-20-11" morph="none" pos="word" start_char="2343">to</TOKEN>
<TOKEN end_char="2350" id="token-20-12" morph="none" pos="word" start_char="2346">reach</TOKEN>
<TOKEN end_char="2352" id="token-20-13" morph="none" pos="word" start_char="2352">a</TOKEN>
<TOKEN end_char="2360" id="token-20-14" morph="none" pos="word" start_char="2354">verdict</TOKEN>
<TOKEN end_char="2361" id="token-20-15" morph="none" pos="punct" start_char="2361">.</TOKEN>
</SEG>
<SEG end_char="2526" id="segment-21" start_char="2363">
<ORIGINAL_TEXT>Larger, well-designed studies are required to confirm our results," said Shahin Merat, the lead author of one of the Journal of Antimicrobial Chemotherapy articles.</ORIGINAL_TEXT>
<TOKEN end_char="2368" id="token-21-0" morph="none" pos="word" start_char="2363">Larger</TOKEN>
<TOKEN end_char="2369" id="token-21-1" morph="none" pos="punct" start_char="2369">,</TOKEN>
<TOKEN end_char="2383" id="token-21-2" morph="none" pos="unknown" start_char="2371">well-designed</TOKEN>
<TOKEN end_char="2391" id="token-21-3" morph="none" pos="word" start_char="2385">studies</TOKEN>
<TOKEN end_char="2395" id="token-21-4" morph="none" pos="word" start_char="2393">are</TOKEN>
<TOKEN end_char="2404" id="token-21-5" morph="none" pos="word" start_char="2397">required</TOKEN>
<TOKEN end_char="2407" id="token-21-6" morph="none" pos="word" start_char="2406">to</TOKEN>
<TOKEN end_char="2415" id="token-21-7" morph="none" pos="word" start_char="2409">confirm</TOKEN>
<TOKEN end_char="2419" id="token-21-8" morph="none" pos="word" start_char="2417">our</TOKEN>
<TOKEN end_char="2427" id="token-21-9" morph="none" pos="word" start_char="2421">results</TOKEN>
<TOKEN end_char="2429" id="token-21-10" morph="none" pos="punct" start_char="2428">,"</TOKEN>
<TOKEN end_char="2434" id="token-21-11" morph="none" pos="word" start_char="2431">said</TOKEN>
<TOKEN end_char="2441" id="token-21-12" morph="none" pos="word" start_char="2436">Shahin</TOKEN>
<TOKEN end_char="2447" id="token-21-13" morph="none" pos="word" start_char="2443">Merat</TOKEN>
<TOKEN end_char="2448" id="token-21-14" morph="none" pos="punct" start_char="2448">,</TOKEN>
<TOKEN end_char="2452" id="token-21-15" morph="none" pos="word" start_char="2450">the</TOKEN>
<TOKEN end_char="2457" id="token-21-16" morph="none" pos="word" start_char="2454">lead</TOKEN>
<TOKEN end_char="2464" id="token-21-17" morph="none" pos="word" start_char="2459">author</TOKEN>
<TOKEN end_char="2467" id="token-21-18" morph="none" pos="word" start_char="2466">of</TOKEN>
<TOKEN end_char="2471" id="token-21-19" morph="none" pos="word" start_char="2469">one</TOKEN>
<TOKEN end_char="2474" id="token-21-20" morph="none" pos="word" start_char="2473">of</TOKEN>
<TOKEN end_char="2478" id="token-21-21" morph="none" pos="word" start_char="2476">the</TOKEN>
<TOKEN end_char="2486" id="token-21-22" morph="none" pos="word" start_char="2480">Journal</TOKEN>
<TOKEN end_char="2489" id="token-21-23" morph="none" pos="word" start_char="2488">of</TOKEN>
<TOKEN end_char="2503" id="token-21-24" morph="none" pos="word" start_char="2491">Antimicrobial</TOKEN>
<TOKEN end_char="2516" id="token-21-25" morph="none" pos="word" start_char="2505">Chemotherapy</TOKEN>
<TOKEN end_char="2525" id="token-21-26" morph="none" pos="word" start_char="2518">articles</TOKEN>
<TOKEN end_char="2526" id="token-21-27" morph="none" pos="punct" start_char="2526">.</TOKEN>
</SEG>
<SEG end_char="2704" id="segment-22" start_char="2528">
<ORIGINAL_TEXT>"A network of five randomised clinical trials has been set up, to test sofosbuvir plus daclatasvir in over 2000 patients with COVID-19, in Iran, Brazil, Egypt, and South Africa.</ORIGINAL_TEXT>
<TOKEN end_char="2528" id="token-22-0" morph="none" pos="punct" start_char="2528">"</TOKEN>
<TOKEN end_char="2529" id="token-22-1" morph="none" pos="word" start_char="2529">A</TOKEN>
<TOKEN end_char="2537" id="token-22-2" morph="none" pos="word" start_char="2531">network</TOKEN>
<TOKEN end_char="2540" id="token-22-3" morph="none" pos="word" start_char="2539">of</TOKEN>
<TOKEN end_char="2545" id="token-22-4" morph="none" pos="word" start_char="2542">five</TOKEN>
<TOKEN end_char="2556" id="token-22-5" morph="none" pos="word" start_char="2547">randomised</TOKEN>
<TOKEN end_char="2565" id="token-22-6" morph="none" pos="word" start_char="2558">clinical</TOKEN>
<TOKEN end_char="2572" id="token-22-7" morph="none" pos="word" start_char="2567">trials</TOKEN>
<TOKEN end_char="2576" id="token-22-8" morph="none" pos="word" start_char="2574">has</TOKEN>
<TOKEN end_char="2581" id="token-22-9" morph="none" pos="word" start_char="2578">been</TOKEN>
<TOKEN end_char="2585" id="token-22-10" morph="none" pos="word" start_char="2583">set</TOKEN>
<TOKEN end_char="2588" id="token-22-11" morph="none" pos="word" start_char="2587">up</TOKEN>
<TOKEN end_char="2589" id="token-22-12" morph="none" pos="punct" start_char="2589">,</TOKEN>
<TOKEN end_char="2592" id="token-22-13" morph="none" pos="word" start_char="2591">to</TOKEN>
<TOKEN end_char="2597" id="token-22-14" morph="none" pos="word" start_char="2594">test</TOKEN>
<TOKEN end_char="2608" id="token-22-15" morph="none" pos="word" start_char="2599">sofosbuvir</TOKEN>
<TOKEN end_char="2613" id="token-22-16" morph="none" pos="word" start_char="2610">plus</TOKEN>
<TOKEN end_char="2625" id="token-22-17" morph="none" pos="word" start_char="2615">daclatasvir</TOKEN>
<TOKEN end_char="2628" id="token-22-18" morph="none" pos="word" start_char="2627">in</TOKEN>
<TOKEN end_char="2633" id="token-22-19" morph="none" pos="word" start_char="2630">over</TOKEN>
<TOKEN end_char="2638" id="token-22-20" morph="none" pos="word" start_char="2635">2000</TOKEN>
<TOKEN end_char="2647" id="token-22-21" morph="none" pos="word" start_char="2640">patients</TOKEN>
<TOKEN end_char="2652" id="token-22-22" morph="none" pos="word" start_char="2649">with</TOKEN>
<TOKEN end_char="2661" id="token-22-23" morph="none" pos="unknown" start_char="2654">COVID-19</TOKEN>
<TOKEN end_char="2662" id="token-22-24" morph="none" pos="punct" start_char="2662">,</TOKEN>
<TOKEN end_char="2665" id="token-22-25" morph="none" pos="word" start_char="2664">in</TOKEN>
<TOKEN end_char="2670" id="token-22-26" morph="none" pos="word" start_char="2667">Iran</TOKEN>
<TOKEN end_char="2671" id="token-22-27" morph="none" pos="punct" start_char="2671">,</TOKEN>
<TOKEN end_char="2678" id="token-22-28" morph="none" pos="word" start_char="2673">Brazil</TOKEN>
<TOKEN end_char="2679" id="token-22-29" morph="none" pos="punct" start_char="2679">,</TOKEN>
<TOKEN end_char="2685" id="token-22-30" morph="none" pos="word" start_char="2681">Egypt</TOKEN>
<TOKEN end_char="2686" id="token-22-31" morph="none" pos="punct" start_char="2686">,</TOKEN>
<TOKEN end_char="2690" id="token-22-32" morph="none" pos="word" start_char="2688">and</TOKEN>
<TOKEN end_char="2696" id="token-22-33" morph="none" pos="word" start_char="2692">South</TOKEN>
<TOKEN end_char="2703" id="token-22-34" morph="none" pos="word" start_char="2698">Africa</TOKEN>
<TOKEN end_char="2704" id="token-22-35" morph="none" pos="punct" start_char="2704">.</TOKEN>
</SEG>
<SEG end_char="2787" id="segment-23" start_char="2706">
<ORIGINAL_TEXT>By October, we should know if this treatment could be approved for worldwide use."</ORIGINAL_TEXT>
<TOKEN end_char="2707" id="token-23-0" morph="none" pos="word" start_char="2706">By</TOKEN>
<TOKEN end_char="2715" id="token-23-1" morph="none" pos="word" start_char="2709">October</TOKEN>
<TOKEN end_char="2716" id="token-23-2" morph="none" pos="punct" start_char="2716">,</TOKEN>
<TOKEN end_char="2719" id="token-23-3" morph="none" pos="word" start_char="2718">we</TOKEN>
<TOKEN end_char="2726" id="token-23-4" morph="none" pos="word" start_char="2721">should</TOKEN>
<TOKEN end_char="2731" id="token-23-5" morph="none" pos="word" start_char="2728">know</TOKEN>
<TOKEN end_char="2734" id="token-23-6" morph="none" pos="word" start_char="2733">if</TOKEN>
<TOKEN end_char="2739" id="token-23-7" morph="none" pos="word" start_char="2736">this</TOKEN>
<TOKEN end_char="2749" id="token-23-8" morph="none" pos="word" start_char="2741">treatment</TOKEN>
<TOKEN end_char="2755" id="token-23-9" morph="none" pos="word" start_char="2751">could</TOKEN>
<TOKEN end_char="2758" id="token-23-10" morph="none" pos="word" start_char="2757">be</TOKEN>
<TOKEN end_char="2767" id="token-23-11" morph="none" pos="word" start_char="2760">approved</TOKEN>
<TOKEN end_char="2771" id="token-23-12" morph="none" pos="word" start_char="2769">for</TOKEN>
<TOKEN end_char="2781" id="token-23-13" morph="none" pos="word" start_char="2773">worldwide</TOKEN>
<TOKEN end_char="2785" id="token-23-14" morph="none" pos="word" start_char="2783">use</TOKEN>
<TOKEN end_char="2787" id="token-23-15" morph="none" pos="punct" start_char="2786">."</TOKEN>
</SEG>
<SEG end_char="2792" id="segment-24" start_char="2790">
<ORIGINAL_TEXT>###</ORIGINAL_TEXT>
<TOKEN end_char="2792" id="token-24-0" morph="none" pos="tag" start_char="2790">###</TOKEN>
<TRANSLATED_TEXT># #</TRANSLATED_TEXT><DETECTED_LANGUAGE /></SEG>
<SEG end_char="3340" id="segment-25" start_char="2795">
<ORIGINAL_TEXT>The papers "The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19", "Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19)," and "Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial," will be available (at Midnight (EST) on August 19th at:</ORIGINAL_TEXT>
<TOKEN end_char="2797" id="token-25-0" morph="none" pos="word" start_char="2795">The</TOKEN>
<TOKEN end_char="2804" id="token-25-1" morph="none" pos="word" start_char="2799">papers</TOKEN>
<TOKEN end_char="2806" id="token-25-2" morph="none" pos="punct" start_char="2806">"</TOKEN>
<TOKEN end_char="2809" id="token-25-3" morph="none" pos="word" start_char="2807">The</TOKEN>
<TOKEN end_char="2816" id="token-25-4" morph="none" pos="word" start_char="2811">impact</TOKEN>
<TOKEN end_char="2819" id="token-25-5" morph="none" pos="word" start_char="2818">of</TOKEN>
<TOKEN end_char="2842" id="token-25-6" morph="none" pos="unknown" start_char="2821">sofosbuvir/daclatasvir</TOKEN>
<TOKEN end_char="2845" id="token-25-7" morph="none" pos="word" start_char="2844">or</TOKEN>
<TOKEN end_char="2855" id="token-25-8" morph="none" pos="word" start_char="2847">ribavirin</TOKEN>
<TOKEN end_char="2858" id="token-25-9" morph="none" pos="word" start_char="2857">in</TOKEN>
<TOKEN end_char="2867" id="token-25-10" morph="none" pos="word" start_char="2860">patients</TOKEN>
<TOKEN end_char="2872" id="token-25-11" morph="none" pos="word" start_char="2869">with</TOKEN>
<TOKEN end_char="2879" id="token-25-12" morph="none" pos="word" start_char="2874">severe</TOKEN>
<TOKEN end_char="2888" id="token-25-13" morph="none" pos="unknown" start_char="2881">COVID-19</TOKEN>
<TOKEN end_char="2890" id="token-25-14" morph="none" pos="punct" start_char="2889">",</TOKEN>
<TOKEN end_char="2892" id="token-25-15" morph="none" pos="punct" start_char="2892">"</TOKEN>
<TOKEN end_char="2902" id="token-25-16" morph="none" pos="word" start_char="2893">Sofosbuvir</TOKEN>
<TOKEN end_char="2906" id="token-25-17" morph="none" pos="word" start_char="2904">and</TOKEN>
<TOKEN end_char="2918" id="token-25-18" morph="none" pos="word" start_char="2908">daclatasvir</TOKEN>
<TOKEN end_char="2927" id="token-25-19" morph="none" pos="word" start_char="2920">compared</TOKEN>
<TOKEN end_char="2932" id="token-25-20" morph="none" pos="word" start_char="2929">with</TOKEN>
<TOKEN end_char="2941" id="token-25-21" morph="none" pos="word" start_char="2934">standard</TOKEN>
<TOKEN end_char="2944" id="token-25-22" morph="none" pos="word" start_char="2943">of</TOKEN>
<TOKEN end_char="2949" id="token-25-23" morph="none" pos="word" start_char="2946">care</TOKEN>
<TOKEN end_char="2952" id="token-25-24" morph="none" pos="word" start_char="2951">in</TOKEN>
<TOKEN end_char="2956" id="token-25-25" morph="none" pos="word" start_char="2954">the</TOKEN>
<TOKEN end_char="2966" id="token-25-26" morph="none" pos="word" start_char="2958">treatment</TOKEN>
<TOKEN end_char="2969" id="token-25-27" morph="none" pos="word" start_char="2968">of</TOKEN>
<TOKEN end_char="2978" id="token-25-28" morph="none" pos="word" start_char="2971">patients</TOKEN>
<TOKEN end_char="2987" id="token-25-29" morph="none" pos="word" start_char="2980">admitted</TOKEN>
<TOKEN end_char="2990" id="token-25-30" morph="none" pos="word" start_char="2989">to</TOKEN>
<TOKEN end_char="2999" id="token-25-31" morph="none" pos="word" start_char="2992">hospital</TOKEN>
<TOKEN end_char="3004" id="token-25-32" morph="none" pos="word" start_char="3001">with</TOKEN>
<TOKEN end_char="3013" id="token-25-33" morph="none" pos="word" start_char="3006">moderate</TOKEN>
<TOKEN end_char="3016" id="token-25-34" morph="none" pos="word" start_char="3015">or</TOKEN>
<TOKEN end_char="3023" id="token-25-35" morph="none" pos="word" start_char="3018">severe</TOKEN>
<TOKEN end_char="3035" id="token-25-36" morph="none" pos="word" start_char="3025">coronavirus</TOKEN>
<TOKEN end_char="3045" id="token-25-37" morph="none" pos="word" start_char="3037">infection</TOKEN>
<TOKEN end_char="3047" id="token-25-38" morph="none" pos="punct" start_char="3047">(</TOKEN>
<TOKEN end_char="3055" id="token-25-39" morph="none" pos="unknown" start_char="3048">COVID-19</TOKEN>
<TOKEN end_char="3058" id="token-25-40" morph="none" pos="punct" start_char="3056">),"</TOKEN>
<TOKEN end_char="3062" id="token-25-41" morph="none" pos="word" start_char="3060">and</TOKEN>
<TOKEN end_char="3064" id="token-25-42" morph="none" pos="punct" start_char="3064">"</TOKEN>
<TOKEN end_char="3074" id="token-25-43" morph="none" pos="word" start_char="3065">Evaluation</TOKEN>
<TOKEN end_char="3077" id="token-25-44" morph="none" pos="word" start_char="3076">of</TOKEN>
<TOKEN end_char="3081" id="token-25-45" morph="none" pos="word" start_char="3079">the</TOKEN>
<TOKEN end_char="3090" id="token-25-46" morph="none" pos="word" start_char="3083">efficacy</TOKEN>
<TOKEN end_char="3093" id="token-25-47" morph="none" pos="word" start_char="3092">of</TOKEN>
<TOKEN end_char="3104" id="token-25-48" morph="none" pos="word" start_char="3095">sofosbuvir</TOKEN>
<TOKEN end_char="3109" id="token-25-49" morph="none" pos="word" start_char="3106">plus</TOKEN>
<TOKEN end_char="3121" id="token-25-50" morph="none" pos="word" start_char="3111">daclatasvir</TOKEN>
<TOKEN end_char="3124" id="token-25-51" morph="none" pos="word" start_char="3123">in</TOKEN>
<TOKEN end_char="3136" id="token-25-52" morph="none" pos="word" start_char="3126">combination</TOKEN>
<TOKEN end_char="3141" id="token-25-53" morph="none" pos="word" start_char="3138">with</TOKEN>
<TOKEN end_char="3151" id="token-25-54" morph="none" pos="word" start_char="3143">ribavirin</TOKEN>
<TOKEN end_char="3155" id="token-25-55" morph="none" pos="word" start_char="3153">for</TOKEN>
<TOKEN end_char="3168" id="token-25-56" morph="none" pos="word" start_char="3157">hospitalized</TOKEN>
<TOKEN end_char="3177" id="token-25-57" morph="none" pos="unknown" start_char="3170">COVID-19</TOKEN>
<TOKEN end_char="3186" id="token-25-58" morph="none" pos="word" start_char="3179">patients</TOKEN>
<TOKEN end_char="3191" id="token-25-59" morph="none" pos="word" start_char="3188">with</TOKEN>
<TOKEN end_char="3200" id="token-25-60" morph="none" pos="word" start_char="3193">moderate</TOKEN>
<TOKEN end_char="3208" id="token-25-61" morph="none" pos="word" start_char="3202">disease</TOKEN>
<TOKEN end_char="3217" id="token-25-62" morph="none" pos="word" start_char="3210">compared</TOKEN>
<TOKEN end_char="3222" id="token-25-63" morph="none" pos="word" start_char="3219">with</TOKEN>
<TOKEN end_char="3231" id="token-25-64" morph="none" pos="word" start_char="3224">standard</TOKEN>
<TOKEN end_char="3236" id="token-25-65" morph="none" pos="word" start_char="3233">care</TOKEN>
<TOKEN end_char="3237" id="token-25-66" morph="none" pos="punct" start_char="3237">:</TOKEN>
<TOKEN end_char="3239" id="token-25-67" morph="none" pos="word" start_char="3239">a</TOKEN>
<TOKEN end_char="3253" id="token-25-68" morph="none" pos="unknown" start_char="3241">single-centre</TOKEN>
<TOKEN end_char="3254" id="token-25-69" morph="none" pos="punct" start_char="3254">,</TOKEN>
<TOKEN end_char="3265" id="token-25-70" morph="none" pos="word" start_char="3256">randomized</TOKEN>
<TOKEN end_char="3276" id="token-25-71" morph="none" pos="word" start_char="3267">controlled</TOKEN>
<TOKEN end_char="3282" id="token-25-72" morph="none" pos="word" start_char="3278">trial</TOKEN>
<TOKEN end_char="3284" id="token-25-73" morph="none" pos="punct" start_char="3283">,"</TOKEN>
<TOKEN end_char="3289" id="token-25-74" morph="none" pos="word" start_char="3286">will</TOKEN>
<TOKEN end_char="3292" id="token-25-75" morph="none" pos="word" start_char="3291">be</TOKEN>
<TOKEN end_char="3302" id="token-25-76" morph="none" pos="word" start_char="3294">available</TOKEN>
<TOKEN end_char="3304" id="token-25-77" morph="none" pos="punct" start_char="3304">(</TOKEN>
<TOKEN end_char="3306" id="token-25-78" morph="none" pos="word" start_char="3305">at</TOKEN>
<TOKEN end_char="3315" id="token-25-79" morph="none" pos="word" start_char="3308">Midnight</TOKEN>
<TOKEN end_char="3317" id="token-25-80" morph="none" pos="punct" start_char="3317">(</TOKEN>
<TOKEN end_char="3320" id="token-25-81" morph="none" pos="word" start_char="3318">EST</TOKEN>
<TOKEN end_char="3321" id="token-25-82" morph="none" pos="punct" start_char="3321">)</TOKEN>
<TOKEN end_char="3324" id="token-25-83" morph="none" pos="word" start_char="3323">on</TOKEN>
<TOKEN end_char="3331" id="token-25-84" morph="none" pos="word" start_char="3326">August</TOKEN>
<TOKEN end_char="3336" id="token-25-85" morph="none" pos="word" start_char="3333">19th</TOKEN>
<TOKEN end_char="3339" id="token-25-86" morph="none" pos="word" start_char="3338">at</TOKEN>
<TOKEN end_char="3340" id="token-25-87" morph="none" pos="punct" start_char="3340">:</TOKEN>
</SEG>
<SEG end_char="3413" id="segment-26" start_char="3343">
<ORIGINAL_TEXT>doi:10.1093/jac/dkaa331 doi:10.1093/jac/dkaa332 doi:10.1093/jac/dkaa334</ORIGINAL_TEXT>
<TOKEN end_char="3365" id="token-26-0" morph="none" pos="unknown" start_char="3343">doi:10.1093/jac/dkaa331</TOKEN>
<TOKEN end_char="3389" id="token-26-1" morph="none" pos="unknown" start_char="3367">doi:10.1093/jac/dkaa332</TOKEN>
<TOKEN end_char="3413" id="token-26-2" morph="none" pos="unknown" start_char="3391">doi:10.1093/jac/dkaa334</TOKEN>
<TRANSLATED_TEXT>doi: 10.1093 / jac / dkaa331. doi: 10.1093 / jac / dkaa332. doi: 10.1093 / jac / dkaa334.</TRANSLATED_TEXT><DETECTED_LANGUAGE>so</DETECTED_LANGUAGE></SEG>
<SEG end_char="3440" id="segment-27" start_char="3416">
<ORIGINAL_TEXT>Direct correspondence to:</ORIGINAL_TEXT>
<TOKEN end_char="3421" id="token-27-0" morph="none" pos="word" start_char="3416">Direct</TOKEN>
<TOKEN end_char="3436" id="token-27-1" morph="none" pos="word" start_char="3423">correspondence</TOKEN>
<TOKEN end_char="3439" id="token-27-2" morph="none" pos="word" start_char="3438">to</TOKEN>
<TOKEN end_char="3440" id="token-27-3" morph="none" pos="punct" start_char="3440">:</TOKEN>
</SEG>
<SEG end_char="3585" id="segment-28" start_char="3443">
<ORIGINAL_TEXT>Dr Andrew Hill Senior Visiting Research Fellow, Liverpool University 70 Pembroke Place Liverpool L69 3GF, UNITED KINGDOM andrewhillmv@gmail.com</ORIGINAL_TEXT>
<TOKEN end_char="3444" id="token-28-0" morph="none" pos="word" start_char="3443">Dr</TOKEN>
<TOKEN end_char="3451" id="token-28-1" morph="none" pos="word" start_char="3446">Andrew</TOKEN>
<TOKEN end_char="3456" id="token-28-2" morph="none" pos="word" start_char="3453">Hill</TOKEN>
<TOKEN end_char="3463" id="token-28-3" morph="none" pos="word" start_char="3458">Senior</TOKEN>
<TOKEN end_char="3472" id="token-28-4" morph="none" pos="word" start_char="3465">Visiting</TOKEN>
<TOKEN end_char="3481" id="token-28-5" morph="none" pos="word" start_char="3474">Research</TOKEN>
<TOKEN end_char="3488" id="token-28-6" morph="none" pos="word" start_char="3483">Fellow</TOKEN>
<TOKEN end_char="3489" id="token-28-7" morph="none" pos="punct" start_char="3489">,</TOKEN>
<TOKEN end_char="3499" id="token-28-8" morph="none" pos="word" start_char="3491">Liverpool</TOKEN>
<TOKEN end_char="3510" id="token-28-9" morph="none" pos="word" start_char="3501">University</TOKEN>
<TOKEN end_char="3513" id="token-28-10" morph="none" pos="word" start_char="3512">70</TOKEN>
<TOKEN end_char="3522" id="token-28-11" morph="none" pos="word" start_char="3515">Pembroke</TOKEN>
<TOKEN end_char="3528" id="token-28-12" morph="none" pos="word" start_char="3524">Place</TOKEN>
<TOKEN end_char="3538" id="token-28-13" morph="none" pos="word" start_char="3530">Liverpool</TOKEN>
<TOKEN end_char="3542" id="token-28-14" morph="none" pos="word" start_char="3540">L69</TOKEN>
<TOKEN end_char="3546" id="token-28-15" morph="none" pos="word" start_char="3544">3GF</TOKEN>
<TOKEN end_char="3547" id="token-28-16" morph="none" pos="punct" start_char="3547">,</TOKEN>
<TOKEN end_char="3554" id="token-28-17" morph="none" pos="word" start_char="3549">UNITED</TOKEN>
<TOKEN end_char="3562" id="token-28-18" morph="none" pos="word" start_char="3556">KINGDOM</TOKEN>
<TOKEN end_char="3585" id="token-28-19" morph="none" pos="unknown" start_char="3564">andrewhillmv@gmail.com</TOKEN>
</SEG>
<SEG end_char="3591" id="segment-29" start_char="3588">
<ORIGINAL_TEXT>(or)</ORIGINAL_TEXT>
<TOKEN end_char="3588" id="token-29-0" morph="none" pos="punct" start_char="3588">(</TOKEN>
<TOKEN end_char="3590" id="token-29-1" morph="none" pos="word" start_char="3589">or</TOKEN>
<TOKEN end_char="3591" id="token-29-2" morph="none" pos="punct" start_char="3591">)</TOKEN>
</SEG>
<SEG end_char="3721" id="segment-30" start_char="3594">
<ORIGINAL_TEXT>Shahin Merat Digestive Disease Research Institute, Tehran University of Medical Sciences Tehran, 32, IRAN shahin.merat@gmail.com</ORIGINAL_TEXT>
<TOKEN end_char="3599" id="token-30-0" morph="none" pos="word" start_char="3594">Shahin</TOKEN>
<TOKEN end_char="3605" id="token-30-1" morph="none" pos="word" start_char="3601">Merat</TOKEN>
<TOKEN end_char="3615" id="token-30-2" morph="none" pos="word" start_char="3607">Digestive</TOKEN>
<TOKEN end_char="3623" id="token-30-3" morph="none" pos="word" start_char="3617">Disease</TOKEN>
<TOKEN end_char="3632" id="token-30-4" morph="none" pos="word" start_char="3625">Research</TOKEN>
<TOKEN end_char="3642" id="token-30-5" morph="none" pos="word" start_char="3634">Institute</TOKEN>
<TOKEN end_char="3643" id="token-30-6" morph="none" pos="punct" start_char="3643">,</TOKEN>
<TOKEN end_char="3650" id="token-30-7" morph="none" pos="word" start_char="3645">Tehran</TOKEN>
<TOKEN end_char="3661" id="token-30-8" morph="none" pos="word" start_char="3652">University</TOKEN>
<TOKEN end_char="3664" id="token-30-9" morph="none" pos="word" start_char="3663">of</TOKEN>
<TOKEN end_char="3672" id="token-30-10" morph="none" pos="word" start_char="3666">Medical</TOKEN>
<TOKEN end_char="3681" id="token-30-11" morph="none" pos="word" start_char="3674">Sciences</TOKEN>
<TOKEN end_char="3688" id="token-30-12" morph="none" pos="word" start_char="3683">Tehran</TOKEN>
<TOKEN end_char="3689" id="token-30-13" morph="none" pos="punct" start_char="3689">,</TOKEN>
<TOKEN end_char="3692" id="token-30-14" morph="none" pos="word" start_char="3691">32</TOKEN>
<TOKEN end_char="3693" id="token-30-15" morph="none" pos="punct" start_char="3693">,</TOKEN>
<TOKEN end_char="3698" id="token-30-16" morph="none" pos="word" start_char="3695">IRAN</TOKEN>
<TOKEN end_char="3721" id="token-30-17" morph="none" pos="unknown" start_char="3700">shahin.merat@gmail.com</TOKEN>
</SEG>
<SEG end_char="3755" id="segment-31" start_char="3724">
<ORIGINAL_TEXT>Disclaimer: AAAS and EurekAlert!</ORIGINAL_TEXT>
<TOKEN end_char="3733" id="token-31-0" morph="none" pos="word" start_char="3724">Disclaimer</TOKEN>
<TOKEN end_char="3734" id="token-31-1" morph="none" pos="punct" start_char="3734">:</TOKEN>
<TOKEN end_char="3739" id="token-31-2" morph="none" pos="word" start_char="3736">AAAS</TOKEN>
<TOKEN end_char="3743" id="token-31-3" morph="none" pos="word" start_char="3741">and</TOKEN>
<TOKEN end_char="3754" id="token-31-4" morph="none" pos="word" start_char="3745">EurekAlert</TOKEN>
<TOKEN end_char="3755" id="token-31-5" morph="none" pos="punct" start_char="3755">!</TOKEN>
<TRANSLATED_TEXT>Disclaimer: AAAS og EurekAlert!</TRANSLATED_TEXT><DETECTED_LANGUAGE>de</DETECTED_LANGUAGE></SEG>
<SEG end_char="3831" id="segment-32" start_char="3757">
<ORIGINAL_TEXT>are not responsible for the accuracy of news releases posted to EurekAlert!</ORIGINAL_TEXT>
<TOKEN end_char="3759" id="token-32-0" morph="none" pos="word" start_char="3757">are</TOKEN>
<TOKEN end_char="3763" id="token-32-1" morph="none" pos="word" start_char="3761">not</TOKEN>
<TOKEN end_char="3775" id="token-32-2" morph="none" pos="word" start_char="3765">responsible</TOKEN>
<TOKEN end_char="3779" id="token-32-3" morph="none" pos="word" start_char="3777">for</TOKEN>
<TOKEN end_char="3783" id="token-32-4" morph="none" pos="word" start_char="3781">the</TOKEN>
<TOKEN end_char="3792" id="token-32-5" morph="none" pos="word" start_char="3785">accuracy</TOKEN>
<TOKEN end_char="3795" id="token-32-6" morph="none" pos="word" start_char="3794">of</TOKEN>
<TOKEN end_char="3800" id="token-32-7" morph="none" pos="word" start_char="3797">news</TOKEN>
<TOKEN end_char="3809" id="token-32-8" morph="none" pos="word" start_char="3802">releases</TOKEN>
<TOKEN end_char="3816" id="token-32-9" morph="none" pos="word" start_char="3811">posted</TOKEN>
<TOKEN end_char="3819" id="token-32-10" morph="none" pos="word" start_char="3818">to</TOKEN>
<TOKEN end_char="3830" id="token-32-11" morph="none" pos="word" start_char="3821">EurekAlert</TOKEN>
<TOKEN end_char="3831" id="token-32-12" morph="none" pos="punct" start_char="3831">!</TOKEN>
</SEG>
<SEG end_char="3925" id="segment-33" start_char="3833">
<ORIGINAL_TEXT>by contributing institutions or for the use of any information through the EurekAlert system.</ORIGINAL_TEXT>
<TOKEN end_char="3834" id="token-33-0" morph="none" pos="word" start_char="3833">by</TOKEN>
<TOKEN end_char="3847" id="token-33-1" morph="none" pos="word" start_char="3836">contributing</TOKEN>
<TOKEN end_char="3860" id="token-33-2" morph="none" pos="word" start_char="3849">institutions</TOKEN>
<TOKEN end_char="3863" id="token-33-3" morph="none" pos="word" start_char="3862">or</TOKEN>
<TOKEN end_char="3867" id="token-33-4" morph="none" pos="word" start_char="3865">for</TOKEN>
<TOKEN end_char="3871" id="token-33-5" morph="none" pos="word" start_char="3869">the</TOKEN>
<TOKEN end_char="3875" id="token-33-6" morph="none" pos="word" start_char="3873">use</TOKEN>
<TOKEN end_char="3878" id="token-33-7" morph="none" pos="word" start_char="3877">of</TOKEN>
<TOKEN end_char="3882" id="token-33-8" morph="none" pos="word" start_char="3880">any</TOKEN>
<TOKEN end_char="3894" id="token-33-9" morph="none" pos="word" start_char="3884">information</TOKEN>
<TOKEN end_char="3902" id="token-33-10" morph="none" pos="word" start_char="3896">through</TOKEN>
<TOKEN end_char="3906" id="token-33-11" morph="none" pos="word" start_char="3904">the</TOKEN>
<TOKEN end_char="3917" id="token-33-12" morph="none" pos="word" start_char="3908">EurekAlert</TOKEN>
<TOKEN end_char="3924" id="token-33-13" morph="none" pos="word" start_char="3919">system</TOKEN>
<TOKEN end_char="3925" id="token-33-14" morph="none" pos="punct" start_char="3925">.</TOKEN>
</SEG>
</TEXT>
</DOC>
</LCTL_TEXT>